Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
暂无分享,去创建一个
M. Lotze | Zuqiang Liu | R. Ravindranathan | Z. Guo | U. Kammula | Zhi Zhu | Stacy J. Kowalsky | N. Obermajer | M. Feist | Congrong Ma | Enyong Dai | Esther Giehl | David L. Bartlett | Andrew J. H. Lee | Roshni Ravindranathan
[1] Erkko Ylösmäki,et al. Design and application of oncolytic viruses for cancer immunotherapy. , 2019, Current opinion in biotechnology.
[2] D. Karlis,et al. Efficacy of Adoptive Therapy with Tumor-infiltrating Lymphocytes and Recombinant Interleukin-2 in Advanced Cutaneous Melanoma: A Systematic Review and Meta-analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Q. Gao,et al. PD1Hi CD8+ T cells correlate with exhausted signature and poor clinical outcome in hepatocellular carcinoma , 2019, Journal of Immunotherapy for Cancer.
[4] G. Kroemer,et al. Effects of interleukin-2 in immunostimulation and immunosuppression , 2019, The Journal of experimental medicine.
[5] D. Bartlett,et al. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics , 2019, Journal of Immunotherapy for Cancer.
[6] Z. Guo,et al. Modifying the cancer-immune set point using vaccinia virus expressing re-designed interleukin-2 , 2018, Nature Communications.
[7] D. Bartlett,et al. Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[8] R. Fouchier,et al. Armed oncolytic viruses: A kick-start for anti-tumor immunity , 2018, Cytokine & Growth Factor Reviews.
[9] G. Kroemer,et al. Heating it up: Oncolytic viruses make tumors ‘hot’ and suitable for checkpoint blockade immunotherapies , 2018, Oncoimmunology.
[10] U. Kammula,et al. Metastasectomy for Tumor-Infiltrating Lymphocytes: An Emerging Operative Indication in Surgical Oncology , 2017, Annals of Surgical Oncology.
[11] J. Maher,et al. Prospects for combined use of oncolytic viruses and CAR T-cells , 2017, Journal of Immunotherapy for Cancer.
[12] C. Bollard,et al. Virus-Specific T Cells for the Immunocompromised Patient , 2017, Front. Immunol..
[13] Michael E. Lassman,et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.
[14] Laurence Zitvogel,et al. The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.
[15] S. Hervás-Stubbs,et al. Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. , 2017, Cancer research.
[16] A. K. Srivastava,et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[17] Z. Guo,et al. Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy , 2017, Nature Communications.
[18] Yaohe Wang,et al. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model , 2016, Clinical Cancer Research.
[19] T. Jiang,et al. Role of IL-2 in cancer immunotherapy , 2016, Oncoimmunology.
[20] Shari Pilon-Thomas,et al. Immune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy , 2016, PloS one.
[21] M. Donia,et al. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen , 2016, Clinical Cancer Research.
[22] F. Marincola,et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. , 2015, The Journal of clinical investigation.
[23] Z. Guo,et al. CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy , 2015, Oncoimmunology.
[24] C. Meijer,et al. Extent and Location of Tumor-Infiltrating Lymphocytes in Microsatellite-Stable Colon Cancer Predict Outcome to Adjuvant Active Specific Immunotherapy , 2015, Clinical Cancer Research.
[25] Yiping Yang,et al. Cancer immunotherapy: harnessing the immune system to battle cancer. , 2015, The Journal of clinical investigation.
[26] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[27] D. Gilham,et al. Efficient and reproducible generation of tumour-infiltrating lymphocytes for renal cell carcinoma , 2015, British Journal of Cancer.
[28] Xiaoliu Zhang,et al. An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites , 2014, Oncotarget.
[29] T. Hagemann,et al. A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer , 2014, Clinical Cancer Research.
[30] C. Guerra,et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. , 2014, Cancer research.
[31] G. Coukos,et al. T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.
[32] D. Bartlett,et al. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity , 2014, Front. Oncol..
[33] Pierre Validire,et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. , 2014, Cancer research.
[34] S. Nimmagadda,et al. The intricate role of CXCR4 in cancer. , 2014, Advances in cancer research.
[35] Derek S. Chan,et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.
[36] D. Bartlett,et al. Oncolytic viruses as therapeutic cancer vaccines , 2013, Molecular Cancer.
[37] W. Gong,et al. Isolation of Mouse Tumor-Infiltrating Leukocytes by Percoll Gradient Centrifugation , 2013 .
[38] M. Bloomston,et al. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer , 2013, Nature Medicine.
[39] T. Waldmann,et al. Superior T memory stem cell persistence supports long-lived T cell memory. , 2013, The Journal of clinical investigation.
[40] J. Flynn,et al. Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. , 2012, Cancer research.
[41] S. Rosenberg,et al. Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.
[42] S. Steinberg,et al. Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.
[43] Z. Guo,et al. Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[44] I. Endo,et al. FOXP3+ Regulatory T Cells and Tumoral Indoleamine 2,3-Dioxygenase Expression Predicts the Carcinogenesis of Intraductal Papillary Mucinous Neoplasms of the Pancreas , 2010, Pancreatology.
[45] Z. Guo,et al. The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host , 2010, Gene Therapy.
[46] S. Kim-Schulze,et al. Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma , 2010, Annals of Surgical Oncology.
[47] C. Turtle,et al. Adoptive transfer of virus-specific and tumor-specific T cell immunity. , 2009, Current opinion in immunology.
[48] S. Qiu,et al. Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma , 2009, Clinical Cancer Research.
[49] F. Errington,et al. Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity , 2008, Clinical Cancer Research.
[50] F. Tangy,et al. Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response. , 2008, Cancer research.
[51] Zihua Zeng,et al. Coadministration of a herpes simplex virus-2 based oncolytic virus and cyclophosphamide produces a synergistic antitumor effect and enhances tumor-specific immune responses. , 2007, Cancer research.
[52] Zhao-You Tang,et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] M. Azuma,et al. Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer , 2007, Clinical Cancer Research.
[54] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[55] Stefan Schneeberger,et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[56] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[57] Bjoern Peters,et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[58] J. Jacobs,et al. Local interleukin 2 therapy is most effective against cancer when injected intratumourally , 2005, Cancer Immunology, Immunotherapy.
[59] S. Libutti,et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.
[60] R. Martuza,et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. , 1999, Human gene therapy.
[61] S. Rosenberg,et al. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. , 1999, Journal of immunology.